Literature DB >> 22320703

Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure.

Roberto Spoladore1, Gabriele Fragasso, Gianluca Perseghin, Francesco De Cobelli, Antonio Esposito, Francesco Maranta, Giliola Calori, Massimo Locatelli, Guido Lattuada, Paola Scifo, Alessandro Del Maschio, Alberto Margonato.   

Abstract

Beta-blockers have been shown to improve left ventricular (LV) function in patients with heart failure. The aim of this study is to non-invasively assess, by means of in vivo 31P-magnetic resonance spectroscopy (31P-MRS), the effects of beta-blockers on LV cardiac phosphocreatine and adenosine triphosphate (PCr/ATP) ratio in patients with heart failure. Ten heart failure patients on full medical therapy were beta-blocked by either carvedilol or bisoprolol. Before and after 3 months of treatment, exercise testing, 2D echocardiography, MRS, New York Heart Association (NYHA) class, ejection fraction (EF), maximal rate-pressure product and exercise metabolic equivalent system (METS) were evaluated. Relative concentrations of PCr and ATP were determined by cardiac 31P-MRS. After beta-blockade, NYHA class decreased (from 2.2 ± 0.54 to 1.9 ± 0.52, P = 0.05), whereas EF (from 33 ± 7 to 44 ± 6%, P = 0.0009) and METS (from 6.74 ± 2.12 to 8.03 ± 2.39, P = 0.01) increased. Accordingly, the mean cardiac PCr/ATP ratio increased by 33% (from 1.48 ± 0.22 to 1.81 ± 0.48, P = 0.03). Beta-blockade-induced symptomatic and functional improvement in patients with heart failure is associated to increased PCr/ATP ratio, indicating preservation of myocardial high-energy phosphate levels.
© 2012 The Authors Fundamental and Clinical Pharmacology © 2012 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22320703     DOI: 10.1111/j.1472-8206.2012.01029.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  11 in total

Review 1.  Left ventricular ejection fraction as therapeutic target: is it the ideal marker?

Authors:  V Katsi; G Georgiopoulos; A Laina; E Koutli; J Parissis; C Tsioufis; P Nihoyannopoulos; D Tousoulis
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 2.  A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition.

Authors:  Ashish Gupta; Brian Houston
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

3.  Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.

Authors:  Gabriele Fragasso
Journal:  Card Fail Rev       Date:  2016-05

Review 4.  Principals and clinical applications of magnetic resonance cardiac spectroscopy in heart failure.

Authors:  Waqas T Qureshi; Usama Bin Nasir
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

5.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Authors:  Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai
Journal:  Basic Res Cardiol       Date:  2014-12-06       Impact factor: 17.165

Review 6.  Ivabradine in Cardiovascular Disease Management Revisited: a Review.

Authors:  Christopher Chen; Gurleen Kaur; Puja K Mehta; Doralisa Morrone; Lucas C Godoy; Sripal Bangalore; Mandeep S Sidhu
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-07       Impact factor: 3.727

7.  Impaired cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with Barth syndrome.

Authors:  Adil Bashir; Kathryn L Bohnert; Dominic N Reeds; Linda R Peterson; Adam J Bittel; Lisa de Las Fuentes; Christina A Pacak; Barry J Byrne; W Todd Cade
Journal:  Physiol Rep       Date:  2017-02

8.  Metoprolol and bisoprolol ameliorate hypertrophy of neonatal rat cardiomyocytes induced by high glucose via the PKC/NF-κB/c-fos signaling pathway.

Authors:  Min Wang; Qingbo Lv; Liding Zhao; Yao Wang; Yi Luan; Zhengwei Li; Guosheng Fu; Wenbin Zhang
Journal:  Exp Ther Med       Date:  2019-12-10       Impact factor: 2.447

9.  Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.

Authors:  Moritz J Hundertmark; Olorunsola F Agbaje; Ruth Coleman; Jyothis T George; Rolf Grempler; Rury R Holman; Hanan Lamlum; Jisoo Lee; Joanne E Milton; Heiko G Niessen; Oliver Rider; Christopher T Rodgers; Ladislav Valkovič; Eleanor Wicks; Masliza Mahmod; Stefan Neubauer
Journal:  ESC Heart Fail       Date:  2021-05-06

Review 10.  Energy metabolism disorders and potential therapeutic drugs in heart failure.

Authors:  Yanan He; Wei Huang; Chen Zhang; Lumeng Chen; Runchun Xu; Nan Li; Fang Wang; Li Han; Ming Yang; Dingkun Zhang
Journal:  Acta Pharm Sin B       Date:  2020-10-14       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.